文献速递乳腺外科

前哨淋巴结阳性黑色素瘤完成性淋巴结清扫的荟萃分析

Meta-analysis of completion lymph node dissection in sentinel lymph node-positive melanoma.
PubMed 文献 · Br J Surg · 2019-03-26

该系统评价与荟萃分析纳入15项研究(13项队列研究7868例,2项RCT 2228例),比较前哨淋巴结阳性黑色素瘤患者行完成性淋巴结清扫(CLND)与观察的生存和复发结局。

要点

  • 前哨淋巴结阳性黑色素瘤患者行CLND相比观察未显著改善生存。
  • CLND相比观察未显著降低复发率。
  • 临床决策需个体化权衡CLND的获益与风险。

核心结论

  • 前哨淋巴结阳性黑色素瘤患者行完成性淋巴结清扫相比观察在生存和复发率上无显著获益。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE和Embase 2000年1月至2017年6月发表的队列研究和RCT。
  • 定性合成纳入15项研究:13项队列研究共7868例,2项RCT共2228例。
  • 定量荟萃分析纳入13项研究。
  • 使用Cochrane偏倚风险工具评估RCT质量,Newcastle-Ottawa量表评估队列研究质量。
  • 合并计算相对危险度或风险比及95%置信区间,用I2检验评估异质性,方案注册于PROSPERO(CRD42017070152)。

临床怎么用

  • 对于前哨淋巴结阳性黑色素瘤患者,CLND不应常规推荐以改善生存或降低复发。
  • 临床决策应个体化,结合患者具体情况和多学科讨论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of completion lymph node dissection (CLND) in patients with sentinel lymph node (SLN)-positive melanoma continues to be debated. This systematic review and meta-analysis evaluated survival and recurrence rate in these patients who underwent CLND, compared with observation. METHODS: A comprehensive MEDLINE and Embase database search was performed for cohort studies and RCTs published between January 2000 and June 2017 that assessed the outcomes of CLND compared with observation in patients with SLN-positive melanoma. The primary outcome was survival and the secondary outcome was recurrence rate. Studies were assessed for quality using the Cochrane risk-of-bias tool for RCTs and Newcastle-Ottawa Scale for cohort studies. Pooled relative risk or hazard ratio with 95 per cent confidence intervals were calculated for each outcome. The extent of heterogeneity between studies was assessed with the I2 test. The protocol was registered in PROSPERO (CRD42017070152). RESULTS: Fifteen studies (13 cohort studies with 7868 patients and 2 RCTs with 2228 patients) were identified for qualitative synthesis. Thirteen studies remained for quantitative meta-analysis. Survival was similar in patients who underwent CLND and those who were observed (risk ratio (RR) for death 0·85, 95 per cent c.i. 0·71 to 1·02). The recurrence rate was also similar (RR 0·91, 0·79 to 1·05). CONCLUSION: Patients with SLN-positive melanoma do not have a significant benefit in survival or recurrence rate if they undergo CLND rather than observation.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Angeles CV, Kang R, Shirai K, et al. Meta-analysis of completion lymph node dissection in sentinel lymph node-positive melanoma. Br J Surg. 2019. PMID: 30912591. doi:10.1002/bjs.11149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。